Michael Harris, DO
Chief Medical Officer
Click here to read more about Dr. Harris
Jon Ward
Chief Executive Officer
Mr. Ward is the CEO of Aspen Clinical Research, LLC. He is responsible for overseeing all programs, budgets, divisions. He is actively involved in study budget and contract negotiations, finance, and corporate development. He received his Bachelors in Business from Penn Foster University with a certification in Business Management and Negotiations from Harvard University.
Mr. Ward has been in clinical operations management for 10 years and has acted as CEO of several private healthcare organizations.
He holds an emeritus seat on the Utah healthcare appropriations committee for the Utah Department of Health as a community liaison, and was formerly recognized on the board for CTAA.
He was recognized by the USBA as one of the top 50 young entrepreneurs in 2006. He is certified in healthcare financial auditing and has worked as a consultant for several healthcare companies.
Wayne Croft MMS, CCRC
Chief Operating Officer
Aspen Clinical Research welcomes Wayne Croft as Chief of Clinical Operations. Mr. Croft earned his Masters Degree of Medical Science and Research from Nova Southeastern Florida University and his Baccalaureate degree in Behavioral and Health Science from the University of Utah. He has spent over 14 years in, pharmaceutical, CRO, and clinical site operations research. Mr. Croft has extensive Phase I clinical research experience in a multiple therapies primarily focusing on the CNS and Cardiovascular indications.
Mr. Croft brings a deep understanding of the clinical research process within the biopharmaceutical and device research industry. His entrepreneurial spirit shows that he has vision and illustrates his ability to effectively execute, build and lead organizations to the highest level possible. He has a strong ability to operationalize and execute clinical protocols to ensure the highest level of excellence and data integrity.
Mr. Croft joined forces with Aspen Clinical Research July of 2008. Combined with Aspen's existing management's experience in Phase II through IV clinical research and Mr. Croft's extensive knowledge of phase I trials strengths Aspen's ability to effectively compete within the pharmaceutical industry.
Ian Dawe, BSN
VP, Business Development & Professional Relations
Mr Dawe is Vice-President, Business Development and Professional Relations for Aspen Clinical Research, LLC. He is responsible for the recruitment of clinical trials and research investigators. He is also responsible for developing and improving relationships with Drug Companies, Sponsors, CRO’s, TMO’s, along with other international, national, and local community research and healthcare organizations.
Mr. Dawe has been in healthcare administration for 15 years. With an emphasis in strategic healthcare operations growth and consultation. He received his Bachelors in Nursing Administration from Saint James College in Florida. He has been working as a Registered Nurse in a multitude of settings including Hospitals, Homecare, and Research.
He holds advanced certifications in Diabetes care, Mental Health , Intensive Care, Palliative care, and Medical Equipment engineering.
He has extensive experience with FDA NDA and Medical Device 510(k) approving research and protocol development. He currently holds a patent on a medical device for diabetics as well as being recognized on several healthcare products as intellectual development.
He was recognized by the USBA as one of the top 50 young entrepreneurs in 2006.
He has consulted for several Universities and Medical Device Manufacturers inclusive of pre-conceptual through product distribution.
S. Matthew Ward
VP Quality Assurance & Regulatory Affairs
Mr. Ward is Vice-President, Quality Assurance & Regulatory Affairs for Aspen Clinical Research, LLC. He is ultimately responsible for the quality of the study data for all research trials and for assuring all site personnel maintain strict protocol adherence through the Standard Operating Procedures, Working Practice Documents and site forms that were created and maintained under his guidance. He is also responsible for the submission and maintenance of all study related regulatory document submissions to the sponsors and IRBs. In addition, he has implemented an internal quality assurance and auditing system that verifies and validates the study data captured in source documents and case report forms. This system lowers the chance of discrepancies occurring and also audits and finds potential queries and flags them for correction before the site monitors arrive for their monitoring visits.
Mr. Ward has been working as a research scientist for over 10 years and has spent the last 8 years working as a Clinical Research Associate monitoring all areas of pharmaceutical drug trials for phase I – IV clinical research studies. His therapeutic knowledge spans several areas including neuropathic pain, diabetic neuropathy, HIV neuropathy, postherpetic neuralgia, diabetes mellitus type II, oncology, allergic rhinitis, hypertension, hypercholesterolemia, dermatology and complex healthy volunteer trials. His work has included the development of many study related documents including clinical trial protocol development, study specific case report form creation and development as well as numerous site tracking forms and monitoring tracking and auditing forms and procedures.
His previous work included helping to develop and maintain the standard operating procedures and product testing specification sheets for one of the largest nutritional supplement companies in the US. This experience along with his years of monitoring and auditing for quality assurance and regulatory documentation make him the perfect fit for ensuring the internal integrity and quality of Aspen Clinical Research.
Mr. Ward is currently recognized by the Association of Clinical Research Professionals as a Certified Clinical Research Associate and has consulted for several small and large pharmaceutical research firms assisting with protocol development, CRF creation and auditing for quality assurance adherence.
|
|
|
